MeritValue

Evommune, Inc.

EVMNdata completeness 88%2 fiscal years on file

Data notes: no data for concept 'totalDebt'; no data for concept 'interestExpense'

The thesis, from the filings

Evommune, Inc. earns about -34% on invested capital, but has diluted owners by 307% over 2 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2024FY 2025
Revenue$7M1$13M1
Net income−$66.8M2−$68.9M2
Operating cash flow−$58.2M3−$76.4M3
Capital expenditure$88,0004$235,0004
Free cash flow (derived)−$58.3M3−$76.7M3
Total debt——
Cash & equivalents$16.3M5$44.1M5
Diluted shares1.5M6.1M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$334.98
your share of equity
Profit it earned you last year
−$112.23
Free cash flow it threw off
−$124.95
Debt you’d be carrying
—

10 shares is a claim on $334.98 of net worth that earned you −$112.23 and generated −$124.95 of cash last year.

iii. Is this a good business?
Moat signal · return on invested capital
-34% avg · 2y
FY24 —FY25 -34%

It earned an average -34% on invested capital over 2 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+307% shares · 2y

Share count is up 307% over 2 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
only 2 years of net income (need ≥3)
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2024-12-31 · accession 0001193125-26-093932 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K · period ending 2024-12-31 · accession 0001193125-26-093932 (NetIncomeLoss)
  3. 10-K · period ending 2024-12-31 · accession 0001193125-26-093932 (NetCashProvidedByUsedInOperatingActivities)
  4. 10-K · period ending 2024-12-31 · accession 0001193125-26-093932 (PaymentsToAcquirePropertyPlantAndEquipment)
  5. 10-K · period ending 2024-12-31 · accession 0001193125-26-093932 (CashAndCashEquivalentsAtCarryingValue)